Features of modern diagnostics and pharmacotherapy of peripartum cardiomyopathy
https://doi.org/10.31549/2542-1174-2021-4-134-148
Abstract
The review considers the features of modern diagnostics, pharmacotherapy and prevention of peripartum cardiomyopathy (PPCM). The significance of modern markers of PPCM is discussed: PAI-1, miR-146a, 16 kDa-PRL, sFlt-1/PlGF, interferongamma, asymmetric dimethylarginine and the role of diagnostic tests (echocardiography, magnetic resonance imaging), the use of which depends on gestational age and the course of PPCM. The information on indications, complications and clinical experience of the use of the main pharmacological drugs used in the treatment of PPCM, taking into account their possible adverse effects on the fetus and lactation, is given. A new algorithm for the treatment of PPCM, called the BOARD concept (bromocriptine, oral therapy of chronic heart failure (CHF), anticoagulants, vasodilators and diuretics), is being considered, in which the use of bromocriptine and anticoagulants is added to the conventional therapy of CHF, as well as preventive measures for the management of patients with PPCM, taking into account the risk of relapse with persistent left ventricular dysfunction during and after pregnancy.
About the Authors
P. G. Madonov
Novosibirsk State Medical University
Russian Federation
Russian Federation
Pavel G. Madonov — Dr. Sci. (Med.), Professor, Head, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine
L. D. Khidirova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Lyudmila D. Khidirova — Dr. Sci. (Med.), Associate Professor, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine
52, Krasny Prospect, Novosibirsk, 630091
V. D. Kazantseva
Moscow Regional Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Valeria D. Kazantseva — Clinical Resident
References
1. Sliwa K., Petrie M.C., Hilfiker-Kleiner D. et al. (2018). Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur. J. Heart Fail., 20 (6), 951–962. doi: 10.1002/ejhf.1178.
2. Sliwa K., Mebazaa A., Hilfiker-Kleiner D. et al. (2017). Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur. J. Heart Fail., 19 (9), 1131–1141. doi: 10.1002/ejhf.780.
3. Hilfiker-Kleiner D., Haghikia A., Masuko D. et al. (2017). Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur. J. Heart Fail., 19 (12), 1723–1728. doi: 10.1002/ejhf.808.
4. Kolte D., Khera S., Aronow W.S. et al. (2014). Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J. Am. Heart Assoc., 3 (3), e001056. doi: 10.1161/JAHA.114.001056.
5. Arany Z., Elkayam U. (2016). Peripartum cardiomyopathy. Circulation, 133 (14), 1397–1409. doi: 10.1161/CIRCULATIONAHA.115.020491.
6. Patten I.S., Rana S., Shahul S. et al. (2012). Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 485 (7398), 333–338. doi: 10.1038/nature11040.
7. Bauersachs J., Arrigo M., Hilfiker-Kleiner D. et al. (2016). Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur. J. Heart Fail., 18 (9), 1096–1105. doi: 10.1002/ejhf.586.
8. Bauersachs J. (2017). Poor outcomes in poor patients?: Peripartum cardiomyopathy — not just black and white. JAMA Cardiol., 2 (11), 1261–1262. doi: 10.1001/jamacardio.2017.3605.
9. Elkayam U., Akhter M.W., Singh H. et al. (2005). Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation, 111 (16), 2050–2055. doi: 10.1161/01.CIR.0000162478.36652.7E.
10. Puri A., Sethi R., Singh B. et al. (2009). Peripartum cardiomyopathy presenting with ventricular tachycardia: a rare presentation. Indian Pacing Electrophysiol J., 9 (3), 186–189.
11. McNamara D.M., Elkayam U., Alharethi R. et al. (2015). Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy-associated cardiomyopathy). J. Am. Coll. Cardiol., 66 (8), 905–914. doi: 10.1016/j.jacc.2015.06.1309.
12. Irizarry O.C., Levine L.D., Lewey J. et al. (2017). Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between african american and non-african american women. JAMA Cardiol., 2 (11), 1256–1260. doi: 10.1001/jamacardio.2017.3574.
13. Bauersachs J., König T., van der Meer P. et al. (2019). Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European society of cardiology study group on peripartum cardiomyopathy. Eur. J. Heart Fail., 21 (7), 827–843. doi: 10.1002/ejhf.1493.
14. Ricke-Hoch M., Hoes M.F., Pfeffer T.J. et al. (2020). In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovasc. Res., 116 (11), 1875–1886. doi: 10.1093/cvr/cvz300.
15. Bajou K., Herkenne S., Thijssen V.L. et al. (2014). PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat. Med., 20 (7), 741–747. doi: 10.1038/nm.3552.
16. Lata I., Gupta R., Sahu S., Singh H. (2009). Emergency management of decompensated peripartum cardiomyo pathy. J. Emerg. Trauma Shock, 2 (2), 124– 128. doi: 10.4103/0974-2700.50748.
17. Sisakian H. (2014). Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J. Cardiol., 6 (6), 478–494. doi: 10.4330/wjc.v6.i6.478.
18. Schelbert E.B., Elkayam U., Cooper L.T. et al. (2017). Myocardial damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. J. Am. Heart Assoc., 6 (4), e005472. doi: 10.1161/JAHA.117.005472.
19. Pierce T., Hovnanian M., Hedgire S., Ghoshhajra B. (2017). Imaging of cardiovascular disease in pregnancy and the peripartum period. Curr. Treat. Options Cardiovasc. Med., 19 (12), 94. doi: 10.1007/s11936-017-0593-8.
20. Ricci F., De Innocentiis C., Verrengia E. et al. (2020). The role of multimodality cardiovascular imaging in peripartum cardiomyopathy. Front. Cardiovasc. Med., 7, 4. doi: 10.3389/fcvm.2020.00004.
21. Tebbe U., Bramlage K., John F. et al. (2016). Endomyocardial biopsy in patients with cardiomyopathy of unknown origin: does specialized center experience apply to a tertiary care hospital? BMC Res. Notes, 9 (1), 459. doi: 10.1186/s13104-016-2263-4.
22. Yancy C.W., Jessup M., Bozkurt B. et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines. Circulation, 128 (16), 1810– 1852. doi: 10.1161/CIR.0b013e31829e8776.
23. Ersbøll A.S., Johansen M., Damm P. et al. (2017). Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. Eur. J. Heart Fail., 19 (12), 1712–1720. doi: 10.1002/ejhf.882.
24. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J. et al. (2018). 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur. Heart J., 39 (34), 3165–3241. doi: 10.1093/eurheartj/ehy340.
25. Hilfiker-Kleiner D., Haghikia A., Berliner D. et al. (2017). Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur. Heart J., 38 (35), 2671–2679. doi: 10.1093/eurheartj/ ehx355.
26. Sliwa K., Blauwet L., Tibazarwa K. et al. (2010). Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation, 121 (13), 1465–1473. doi: 10.1161/CIRCULATIONAHA.109.901496.
27. Haghikia A., Podewski E., Libhaber E. et al. (2013). Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol., 108 (4), 366. doi: 10.1007/s00395-013-0366-9.
28. Azibani F., Sliwa K. (2018). Peripartum cardiomyopathy: an update. Curr. Heart Fail Rep., 15 (5), 297–306. doi: 10.1007/s11897-018-0404-x.
29. Koenig T., Bauersachs J., Hilfiker-Kleiner D. (2018). Bromocriptine for the treatment of peripartum cardiomyopathy. Card. Fail. Rev., 4 (1), 46–49. doi: 10.15420/cfr.2018:2:2.
30. Maas A.H.E.M., Rosano G., Cifkova R. et al. (2021). Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J., 42 (10), 967–984. doi: 10.1093/eurheartj/ehaa1044.
31. Hilfiker-Kleiner D., Haghikia A., Nonhoff J., Bauersachs J. (2015). Peripartum cardiomyopathy: current management and future perspectives. Eur. Heart J., 36 (18), 1090–1097. doi: 10.1093/eurheartj/ehv009.
32. Johnson-Coyle L., Jensen L., Sobey A. (2012). American College of Cardiology Foundation; American Heart Association. Peripartum cardiomyopathy: review and practice guidelines. Am. J. Crit. Care, 21 (2), 89–98. doi: 10.4037/ajcc2012163.
33. Halliday B.P., Wassall R., Lota A.S. et al. (2019). Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet, 393 (10166), 61–73. doi: 10.1016/S0140-6736(18)32484-X.
34. Amos A.M., Jaber W.A., Russell S.D. (2006). Improved outcomes in peripartum cardiomyopathy with contemporary. Am. Heart J., 152 (3), 509–513. doi: 10.1016/j.ahj.2006.02.008.
35. Merken J., Brunner-La Rocca H.P., Weerts J. et al. (2018). Heart failure with recovered ejection fraction. J. Am. Coll. Cardiol., 72 (13), 1557–1558. doi: 10.1016/j.jacc.2018.06.070.
36. Ponikowski P., Voors A.A., Anker S.D. et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J., 37 (27), 2129–2200. doi: 10.1093/eurheartj/ehw128.
37. Koenig T., Hilfiker-Kleiner D., Bauersachs J. (2018). Peripartum cardiomyopathy. Herz, 43 (5), 431–437. doi: 10.1007/s00059-018-4709-z.
38. Duncker D., Haghikia A., König T. et al. (2014). Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function — value of the wearable cardioverter/defibrillator. Eur. J. Heart Fail., 16 (12), 1331–1336. doi: 10.1002/ejhf.188.
39. Haghikia A., Röntgen P., Vogel-Claussen J. et al. (2015). Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Fail., 2 (4), 139–149. doi: 10.1002/ehf2.12059.
40. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J. et al. (2019). 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Kardiol. Pol., 77 (3), 245–326. doi: 10.5603/KP.2019.0049.
41. Fett J.D., Christie L.G., Carraway R.D., Murphy J.G. (2005). Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin. Proc., 80 (12), 1602–1606. doi: 10.4065/80.12.1602.
42. Elkayam U., Tummala P.P., Rao K. et al. (2001). Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N. Engl J. Med., 344 (21), 1567–1571. doi: 10.1056/NEJM200105243442101.
43. Kazantseva V.D., Khidirova L.D., Kokoulina N.A. (2021). Current understanding of pathophysiological mechanisms of peripartal cardiomyopathy. Med. Alphabet, 17, 76–80. doi: 10.33667/2078-5631-2021-17-76-80.
Review
For citations:
Madonov P.G., Khidirova L.D., Kazantseva V.D. Features of modern diagnostics and pharmacotherapy of peripartum cardiomyopathy. Journal of Siberian Medical Sciences. 2021;(4):134-148. https://doi.org/10.31549/2542-1174-2021-4-134-148
Views:
175
Email this article 